EGFR and lung cancer: For example, FAM83A has been identified as exhibiting a tumor-promoting role in lung cancer and BRCA and can cause epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) resistance by activating the phosphatidylinositol-3-kinase-protein kinase B (PI3K-AKT) and mitogen-activated protein kinase (MAPK) signaling pathways (Li et al., 2005; Wang et al., 2015).